References
- Steinherz L J, Steinherz P G, Tan C H. Cardiac failure and dysrhythmias 6–19 years after anthracycline therapy: A series of 15 patients. Med Pediatr Oncol. 1995; 24: 352–361
- Lang D, Hilger F, Binswanger J. Late effects of anthracycline therapy in childhood in relation to the function of the heart at rest and under physical stress. Eur J. Pediatr. 1995; 154: 340–345
- Prat C B, Ransom J L, Evans W E. Age-related Adriamycin cardiotoxicity in children. Cancer Treat Rep. 1978; 63: 827–834
- Myers C E, McGuire P, Liss R H. Adriamycin: The role of lipid peroxidation in cardiac toxicity and tumor response. Science 1977; 197: 165–167
- Doroshow J H, Reeves J. Anthracycline enhanced oxygen radical formation in the heart. Proc AACR. 1980; 21: 266
- Speyer J L, Green M D, Kramer E. Protective effect of the bispiperazinedione ICRF187 against doxorubicin-induced cardiac toxicity in women with advanced breast cancer. N Engl J Med. 1988; 319: 745–752
- Speyer J L, Green M D, Zeleniuch-Jaquotte A. ICRF permits longer treatment with doxorubicin in women with breast cancer. J Clin Oncol. 1992; 10: 117–127
- Bu'Lock F A, Gabriel H M, Oakhill A. Cardioprotection by ICRF187 against high dose anthracycline toxicity in children with malignant disease. Br Heart J. 1993; 70: 185–188
- Wexler L H, Berg S, Andrich M. ICRF-187 reduces doxorubicin-induced cardiotoxicity with no impact on response to chemotherapy. Asco Meeting, Dallas, TX, 1994, no. 1434
- Rubio M E, Wiegman A, Naeff M SJ. ICRF-187 (Cardioxane) protection against doxorubicin induced cardiomyopathy in paediatric osteosarcoma patients. Asco Meeting, San Francisco, CA, 1995